Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gaemers

Showing results (41-50 of 64) with videos related to

Pageof 7
Sort By:
The Lancet. Gastroenterology & Hepatology|November 16, 2025
Safety and pharmacokinetics of SOR102, an oral bispecific inhibitor of TNF and interleukin-23 in healthy participants and patients with ulcerative colitis: a first-in-human, double-blind, randomised, placebo-controlled, phase 1 trialVipul Jairath, Silvio Danese, Geert R D'Haens, et al.
Biochimica Et Biophysica Acta|August 1, 2016
Bile acid receptor agonists INT747 and INT777 decrease oestrogen deficiency-related postmenopausal obesity and hepatic steatosis in miceMonique C de Oliveira, Eduardo H Gilglioni, Bouke A de Boer, et al.
American Journal of Hematology|August 2, 2017
Outcomes after 18 months of eliglustat therapy in treatment-naïve adults with Gaucher disease type 1: The phase 3 ENGAGE trialPramod K Mistry, Elena Lukina, Hadhami Ben Turkia, et al.
Blood|February 8, 2017
Eliglustat maintains long-term clinical stability in patients with Gaucher disease type 1 stabilized on enzyme therapyTimothy M Cox, Guillermo Drelichman, Renata Cravo, et al.
Molecular Genetics and Metabolism|December 8, 2022
Venglustat, an orally administered glucosylceramide synthase inhibitor: Assessment over 3 years in adult males with classic Fabry disease in an open-label phase 2 study and its extension studyPatrick B Deegan, Ozlem Goker-Alpan, Tarekegn Geberhiwot, et al.
American Journal of Hematology|June 23, 2021
Clinical outcomes after 4.5 years of eliglustat therapy for Gaucher disease type 1: Phase 3 ENGAGE trial final resultsPramod K Mistry, Elena Lukina, Hadhami Ben Turkia, et al.
Biochimica Et Biophysica Acta. Molecular Basis of Disease|April 14, 2018
Sex differences in the development of hepatic steatosis in cafeteria diet-induced obesity in young miceFabiana Rodrigues Silva Gasparin, Fernando Olinto Carreño, Juliana Moraes Mewes, et al.
The Journal of Nutrition|February 27, 2015
Dietary Marine n-3 PUFAs Do Not Affect Stress-Induced Visceral Hypersensitivity in a Rat Maternal Separation ModelSophie A van Diest, Lieke W J van den Elsen, Allison J Klok, et al.
Alimentary Pharmacology & Therapeutics|April 16, 2019
Evaluation of optimal biopsy location for assessment of histological activity, transcriptomic and immunohistochemical analyses in patients with active Crohn's diseaseGregor Novak, Toer Stevens, Tanja Van Viegen, et al.
Journal of Parkinson'S Disease|December 13, 2021
Safety, Pharmacokinetics, and Pharmacodynamics of Oral Venglustat in Patients with Parkinson's Disease and a GBA Mutation: Results from Part 1 of the Randomized, Double-Blinded, Placebo-Controlled MOVES-PD TrialM Judith Peterschmitt, Hidemoto Saiki, Taku Hatano, et al.
Pageof 7

Showing results (41-50 of 64) with videos related to

Sort By:
Pageof 7
The Lancet. Gastroenterology & Hepatology|November 16, 2025
Safety and pharmacokinetics of SOR102, an oral bispecific inhibitor of TNF and interleukin-23 in healthy participants and patients with ulcerative colitis: a first-in-human, double-blind, randomised, placebo-controlled, phase 1 trialVipul Jairath, Silvio Danese, Geert R D'Haens, et al.
Biochimica Et Biophysica Acta|August 1, 2016
Bile acid receptor agonists INT747 and INT777 decrease oestrogen deficiency-related postmenopausal obesity and hepatic steatosis in miceMonique C de Oliveira, Eduardo H Gilglioni, Bouke A de Boer, et al.
American Journal of Hematology|August 2, 2017
Outcomes after 18 months of eliglustat therapy in treatment-naïve adults with Gaucher disease type 1: The phase 3 ENGAGE trialPramod K Mistry, Elena Lukina, Hadhami Ben Turkia, et al.
Blood|February 8, 2017
Eliglustat maintains long-term clinical stability in patients with Gaucher disease type 1 stabilized on enzyme therapyTimothy M Cox, Guillermo Drelichman, Renata Cravo, et al.
Molecular Genetics and Metabolism|December 8, 2022
Venglustat, an orally administered glucosylceramide synthase inhibitor: Assessment over 3 years in adult males with classic Fabry disease in an open-label phase 2 study and its extension studyPatrick B Deegan, Ozlem Goker-Alpan, Tarekegn Geberhiwot, et al.
American Journal of Hematology|June 23, 2021
Clinical outcomes after 4.5 years of eliglustat therapy for Gaucher disease type 1: Phase 3 ENGAGE trial final resultsPramod K Mistry, Elena Lukina, Hadhami Ben Turkia, et al.
Biochimica Et Biophysica Acta. Molecular Basis of Disease|April 14, 2018
Sex differences in the development of hepatic steatosis in cafeteria diet-induced obesity in young miceFabiana Rodrigues Silva Gasparin, Fernando Olinto Carreño, Juliana Moraes Mewes, et al.
The Journal of Nutrition|February 27, 2015
Dietary Marine n-3 PUFAs Do Not Affect Stress-Induced Visceral Hypersensitivity in a Rat Maternal Separation ModelSophie A van Diest, Lieke W J van den Elsen, Allison J Klok, et al.
Alimentary Pharmacology & Therapeutics|April 16, 2019
Evaluation of optimal biopsy location for assessment of histological activity, transcriptomic and immunohistochemical analyses in patients with active Crohn's diseaseGregor Novak, Toer Stevens, Tanja Van Viegen, et al.
Journal of Parkinson'S Disease|December 13, 2021
Safety, Pharmacokinetics, and Pharmacodynamics of Oral Venglustat in Patients with Parkinson's Disease and a GBA Mutation: Results from Part 1 of the Randomized, Double-Blinded, Placebo-Controlled MOVES-PD TrialM Judith Peterschmitt, Hidemoto Saiki, Taku Hatano, et al.
Pageof 7